Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
115 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2016', provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) - The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects - The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10 Therapeutics Development 11 Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 12 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 17 Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 19 AbbVie Inc. 19 Amarantus Bioscience Holdings, Inc. 20 Astellas Pharma Inc. 21 AstraZeneca Plc 22 Avineuro Pharmaceuticals, Inc. 23 Bristol-Myers Squibb Company 24 Eli Lilly and Company 25 FORUM Pharmaceuticals Inc. 26 H. Lundbeck A/S 27 Intra-Cellular Therapies, Inc. 28 Iproteos S.L. 29 Luc Therapeutics, Inc. 30 Neuralstem, Inc. 31 Pfizer Inc. 32 Saniona AB 33 SK Biopharmaceuticals Co., Ltd. 34 Spherium Biomed S.L. 35 Sunovion Pharmaceuticals Inc. 36 Takeda Pharmaceutical Company Limited 37 Vanda Pharmaceuticals Inc. 38 Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment 39 Assessment by Monotherapy Products 39 Assessment by Target 40 Assessment by Mechanism of Action 42 Assessment by Route of Administration 44 Assessment by Molecule Type 45 Drug Profiles 47 A-431404 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 AN-761 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AQW-051 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ASP-4345 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ASP-5736 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 AUT-1 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AUT-6 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AUT-9 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 AVL-3288 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AVN-211 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 DSP-3748 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 eltoprazine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 encenicline hydrochloride - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 erteberel - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 FRM-17874 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 IC-041 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 IPR-001 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 IPR-088 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 IPR-19 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 ITI-214 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 LUAF-64280 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NSI-189 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PF-04958242 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PNU-120596 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 roflumilast - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 SEN-15924 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 SKL-15508 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 SKL-A4R - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules for Cognitive Impairment Associated with Schizophrenia - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 SP-14040 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TAK-058 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 TAK-831 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 TAK-915 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 VU-0467154 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Cognitive Impairment Associated With Schizophrenia (CIAS) - Recent Pipeline Updates 93 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects 106 Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products 108 Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones 109 Featured News & Press Releases 109 Nov 11, 2015: FORUM Pharmaceuticals Announces Removal of Partial Clinical Hold on Phase 3 Encenicline Program for Cognitive Impairment in Schizophrenia 109 Sep 14, 2015: FORUM Pharmaceuticals Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer's Disease and Cognitive Impairment in Schizophrenia 109 Jul 15, 2015: FORUM Pharmaceuticals Announces Publication of Encenicline Phase 2 Clinical Trial Results for Cognitive Impairment in Schizophrenia 109 Jun 22, 2015: FORUM Pharmaceuticals Receives FDA Fast Track Designation for Lead Compound Encenicline to Treat Cognitive Impairment in Schizophrenia 110 Jun 11, 2015: FORUM Pharmaceuticals Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial Program of Encenicline for Cognitive Impairment in Schizophrenia 111 Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant 112 Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia 112 Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor 112 Appendix 114 Methodology 114 Coverage 114 Secondary Research 114 Primary Research 114 Expert Panel Validation 114 Contact Us 114 Disclaimer 115
List of Tables Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Development by Companies, H1 2016 (Contd..1) 18 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H1 2016 19 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 20 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H1 2016 21 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2016 22 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 23 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H1 2016 24 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H1 2016 25 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H1 2016 26 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H1 2016 27 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 28 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H1 2016 29 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics, Inc., H1 2016 30 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H1 2016 31 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H1 2016 32 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H1 2016 33 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 34 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed S.L., H1 2016 35 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 36 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 38 Assessment by Monotherapy Products, H1 2016 39 Number of Products by Stage and Target, H1 2016 41 Number of Products by Stage and Mechanism of Action, H1 2016 43 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Cognitive Impairment Associated With Schizophrenia (CIAS) Therapeutics - Recent Pipeline Updates, H1 2016 93 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2016 106 Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H1 2016 107 Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2016 108
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
